Rob Lynch
About Rob Lynch
Rob Lynch serves as the Associate Director of Validation at Kite Pharma, where he has worked since 2019. He has extensive experience in validation management, having previously held roles at GlaxoSmithKline and Human Genome Sciences, and has contributed to regulatory submissions for multiple pharmaceutical products.
Work at Kite Pharma
Rob Lynch has served as the Associate Director of Validation at Kite Pharma since 2019. In this role, he is responsible for the planning, execution, and oversight of the Commissioning, Qualification, and Validation (CQV) processes for the TCF05 Facility located in Urbana, MD. His position involves ensuring that all validation activities meet regulatory standards and support the company's commitment to quality in biopharmaceutical manufacturing.
Previous Experience at GlaxoSmithKline
Before joining Kite Pharma, Rob Lynch worked at GlaxoSmithKline as a Validation Manager for 20 years, from 1999 to 2019. His tenure at the Rockville, MD facility allowed him to gain extensive experience in validation processes within the pharmaceutical industry. His responsibilities included overseeing validation activities and ensuring compliance with regulatory requirements.
Background in Human Genome Sciences
Rob Lynch also held the position of Associate Director of Validation at Human Genome Sciences from 1999 to 2012. This role contributed to his expertise in validation and compliance, further solidifying his career in the biopharmaceutical sector. His experience in this position laid the groundwork for his later roles in validation management.
Education and Expertise
Rob Lynch earned a Bachelor of Science degree in Chemistry from Towson University, where he studied from 1987 to 1993. His educational background in chemistry provides a solid foundation for his work in validation and regulatory compliance within the pharmaceutical industry.
Regulatory Audit Participation
Throughout his career, Rob Lynch has participated in numerous regulatory audits conducted by agencies such as the FDA, EMA, and various international organizations, including Health Canada and ANVISA in Brazil. His involvement in these audits demonstrates his comprehensive understanding of regulatory standards and his commitment to maintaining compliance in the biopharmaceutical field.